S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

23andMe Stock Forecast, Price & News

-0.35 (-4.38%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
3.43 million shs
Average Volume
2.46 million shs
Market Capitalization
$3.12 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ME News and Ratings via Email

Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter.

About 23andMe

23andMe Holding Co. operates as a consumer genetics and research company. The company provides a crowdsourced platform for genetic research. Its platform has generated various publications on the genetic underpinnings of a range of diseases, conditions, and traits, as well as enables it in pursuing drug discovery programs rooted in human genetics across various disease areas, including oncology, respiratory, and cardiovascular diseases, as well as other therapeutic areas. The company was founded in 2006 and is based in Sunnyvale, California.


23andMe (NASDAQ:ME) Shares Gap Up to $7.54
December 2, 2021 |  americanbankingnews.com
23andMe (NASDAQ:ME) Shares Down 6.2%
November 30, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Sales & Book Value

Annual Sales
Book Value
1.62 per share


Pretax Margin




Free Float
Market Cap
$3.12 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.82 out of 5 stars

Medical Sector

834th out of 1,388 stocks

Pharmaceutical Preparations Industry

399th out of 668 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

23andMe (NASDAQ:ME) Frequently Asked Questions

Is 23andMe a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" 23andMe stock.
View analyst ratings for 23andMe
or view top-rated stocks.

When is 23andMe's next earnings date?

23andMe is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for 23andMe

How were 23andMe's earnings last quarter?

23andMe Holding Co. (NASDAQ:ME) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.09.
View 23andMe's earnings history

What guidance has 23andMe issued on next quarter's earnings?

23andMe issued an update on its FY 2022 earnings guidance on Thursday, December, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $250 million-$260 million, compared to the consensus revenue estimate of $256.12 million.

What price target have analysts set for ME?

2 analysts have issued twelve-month price targets for 23andMe's shares. Their forecasts range from 13.00 to 14.00. On average, they anticipate 23andMe's stock price to reach 13.50 in the next twelve months. This suggests a possible upside of 76.5% from the stock's current price.
View analysts' price targets for 23andMe
or view top-rated stocks among Wall Street analysts.

Who are 23andMe's key executives?

23andMe's management team includes the following people:
  • Ms. Anne Wojcicki, Co-Founder, CEO, Pres & Director
  • Mr. Steven J. Schoch, CFO & Treasurer (Age 62, Pay $582.83k)
  • Ms. Kathy L. Hibbs J.D., Esq., Chief Legal & Regulatory Officer and Sec. (Age 57, Pay $558.53k)
  • Dr. Kenneth J. Hillan, Head of Therapeutics (Age 60, Pay $557.62k)
  • Ms. Katie Watson, VP of Communications
  • Mr. Fred Kohler, VP of People
  • Mr. Mike Polcari, VP & Chief Architect
  • Mr. David Baker, Chief Security Officer
  • Mr. Kumar Iyer, Head of Product
  • Dr. Jennifer Low, Head of Therapeutics Devel. (Age 52)

What is 23andMe's stock symbol?

23andMe trades on the NASDAQ under the ticker symbol "ME."

Who are 23andMe's major shareholders?

23andMe's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Casdin Capital LLC (0.45%), BlackRock Inc. (0.28%), Morgan Stanley (0.28%), Liberty Street Advisors Inc. (0.21%), Geode Capital Management LLC (0.19%) and Millennium Management LLC (0.10%).

Which major investors are selling 23andMe stock?

ME stock was sold by a variety of institutional investors in the last quarter, including Casdin Capital LLC, Millennium Management LLC, Citadel Advisors LLC, Morgan Stanley, Jane Street Group LLC, Wolverine Trading LLC, Advisor Group Holdings Inc., and Raymond James Financial Services Advisors Inc..

Which major investors are buying 23andMe stock?

ME stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Granahan Investment Management Inc. MA, Cambridge Investment Research Advisors Inc., Ionic Capital Management LLC, SG Americas Securities LLC, M&G Investment Management Ltd., and Cubist Systematic Strategies LLC.

How do I buy shares of 23andMe?

Shares of ME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 23andMe's stock price today?

One share of ME stock can currently be purchased for approximately 7.65.

How much money does 23andMe make?

23andMe has a market capitalization of $3.12 billion.

How many employees does 23andMe have?

23andMe employs 572 workers across the globe.

What is 23andMe's official website?

The official website for 23andMe is vgacquisition.com.

Where are 23andMe's headquarters?

How can I contact 23andMe?

23andMe's mailing address is 65 BLEECKER STREET 6TH FLOOR, NEW YORK NY, 10012. The company can be reached via phone at 650-938-6300.

This page was last updated on 12/6/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.